Hyperhidrosis is excessive sweating beyond the body’s thermoregulatory requirement. It is divided into primary (idiopathic, focal, often beginning in adolescence) and secondary (caused by underlying medical conditions or medications). Core Aesthetics — consultation-first.
The word itself comes from the Greek: hyper meaning excessive, and hidrosis meaning sweating. The diagnosis is made clinically rather than by laboratory test, although a starch iodine test or gravimetric measurement can quantify sweat production where useful. The threshold for diagnosis is not a particular volume of sweat but rather a clinical pattern: sweating that interferes with daily activity, occurs at least once a week, has been present for at least six months, and cannot be better explained by another cause.
This is one of the most under recognised conditions in cosmetic and dermatological medicine. The estimated prevalence in the general population is around two to three percent, but a substantial proportion of affected people have not raised the issue with a healthcare provider, often because they do not realise it is a recognised condition with established treatment.
Primary versus secondary hyperhidrosis
The clinical distinction between primary and secondary hyperhidrosis is the starting point of any assessment. Primary hyperhidrosis is idiopathic, meaning no identifiable underlying cause. It is typically focal (affecting specific body regions: underarms, palms, soles, face), bilateral and symmetrical, often runs in families, usually begins in childhood or adolescence, and tends to occur during waking hours rather than during sleep.
Secondary hyperhidrosis is caused by an underlying medical condition or by medication. The pattern is often generalised rather than focal, can begin in adulthood, may occur during sleep, and may be associated with other systemic symptoms. Causes include thyroid dysfunction, diabetes, infection, certain medications (particularly some antidepressants and opioids), menopause and other hormonal changes, certain malignancies, and a long list of less common conditions. Secondary hyperhidrosis is treated by addressing the underlying cause, not by neuromodulator injection of the affected region.
Why the distinction matters in practice
This distinction shapes the consultation. A patient who arrives describing bilateral underarm sweating present since adolescence, occurring during the day, in an otherwise healthy adult with no medication contributors, fits the primary focal axillary picture and is a reasonable candidate for cosmetic class neuromodulator treatment. A patient describing generalised sweating beginning in the last twelve months in an adult with no prior history calls for a different conversation, typically referral back to general practice for systemic workup before any cosmetic treatment is considered.
Treating focal symptoms when the underlying cause is systemic does not address the actual problem and can delay appropriate medical care. This is one of the consultation outcomes where we will defer treatment, even when the patient has come specifically requesting it.
The anatomy of sweating
Two main types of sweat gland produce the physical phenomenon. Eccrine glands are distributed widely across the body, with the highest density in the underarms, palms, soles and forehead. They produce a thin, watery sweat that is the body principal mechanism for thermoregulation through evaporative cooling. Apocrine glands are concentrated in the axillae and the perineum, become functional at puberty, and produce a thicker secretion that interacts with skin bacteria to produce body odour.
Both contribute to underarm wetness, but eccrine glands produce most of the visible volume. The eccrine sudomotor nerves are unusual within the sympathetic nervous system because they use acetylcholine as their neurotransmitter, where most other sympathetic postganglionic nerves use noradrenaline. This is what makes the eccrine system susceptible to the same neuromodulator that is used to treat muscular cosmetic indications.
Common patterns by region
Primary focal hyperhidrosis affects different regions in different patients, and the treatment options vary by region. Axillary hyperhidrosis (underarms) responds well to neuromodulator injection and is the most commonly treated focal pattern in cosmetic practice. Palmar hyperhidrosis (palms) also responds, but treatment is technically more demanding and carries a small risk of transient grip weakness, so referral to a hand experienced practitioner is often appropriate. Plantar hyperhidrosis (soles) is treatable but often less satisfactory because of the difficulty of injection and the duration of effect. Craniofacial hyperhidrosis can be addressed but requires careful regional planning.
At Core Aesthetics our principal hyperhidrosis treatment is axillary. Other regional patterns are discussed at consultation and referred where another practice setting is more appropriate.
Diagnosis: history first, instruments second
The diagnosis of primary focal hyperhidrosis is largely a clinical one, made on history and presentation. The validated diagnostic criteria require focal, visible, excessive sweating of at least six months duration without apparent cause, with at least two of: bilateral and symmetrical, impairing daily activities, frequency of at least one episode weekly, age of onset under 25, positive family history, or cessation during sleep.
A starch iodine test can identify the precise area of active sweating and is useful for treatment mapping. Gravimetric measurement (weighing absorbent paper before and after a defined collection period) can quantify the response to treatment. Neither is necessary for diagnosis. The validated severity scoring instrument we commonly use is the Hyperhidrosis Disease Severity Scale, a four point patient rated tool that captures functional impact.
The conventional treatment ladder
Management of primary focal hyperhidrosis has a conventional escalation. First line treatment is topical: aluminium chloride antiperspirants, available in over the counter and prescription strengths. These are useful for many patients, particularly with milder presentations, but cause skin irritation in a substantial minority and provide insufficient control for moderate to severe disease.
Second line treatment for axillary hyperhidrosis where topical strategies have been inadequate is neuromodulator injection. Other modalities (microwave thermolysis, iontophoresis for palmar disease, oral anticholinergic medications) have specific roles but each carries trade offs. Surgical sympathectomy was historically considered for severe disease but is now usually reserved for cases where other treatment has failed, because of the substantial risk of permanent compensatory sweating elsewhere.
How neuromodulator treatment works in this context
The mechanism is the same as in muscular cosmetic indications: the prescription neuromodulator binds to nerve terminals and blocks the release of acetylcholine. In the case of eccrine sweat glands, the blockade is at the neuro glandular junction rather than the neuromuscular junction, but the principle is identical. Without acetylcholine reaching the gland, sweat production is substantially reduced for the duration of the blockade.
Published clinical trials show meaningful response in around 94 percent of treated patients at four weeks. The duration of effect for hyperhidrosis is generally longer than the equivalent dose used in muscular cosmetic indications, with median first treatment durations around five and a half months and median repeat treatment durations around eight and a half months. Compensatory sweating elsewhere is rare and, when reported, mild.
What we do not claim
Several common patient expectations of hyperhidrosis treatment do not match the clinical reality and we name them at consultation. The first is that one treatment will cure the condition. It will not. The treatment is reversible and requires periodic retreatment, typically two to three times per year depending on individual duration of effect. The second is that all sweating will be eliminated. It will not. The treatment substantially reduces production from treated glands. Some baseline sweating may persist and is generally clinically appropriate, because some sweating is part of normal thermoregulation. The third is that the response will be identical at every treatment. Individual responses vary, and the plan adapts to actual response across cycles.
AHPRA September 2025 and what it changed
The AHPRA guidelines for nonsurgical cosmetic procedures that came into force in September 2025 require an in person or video consultation with the prescribing practitioner each time a aesthetic treatment is prescribed, even for repeat patients. Asynchronous prescribing by text or online is no longer acceptable practice. Suitability assessment must explicitly address motivations and expectations.
For hyperhidrosis treatment, this codifies what consultation based practices were already doing. The retreatment cycle includes a brief but real consultation each time, not just a treatment booking. The practical effect for patients is greater continuity of clinical attention rather than additional administrative friction.
What we will not say in marketing
Australian regulation prohibits the advertising of Schedule 4 prescription medicines to the public. That includes the brand names, abbreviations and hashtags associated with aesthetic treatment products, including those used for hyperhidrosis. We can talk in clinical detail about mechanism, dose ranges and response profile. We do not name brands, abbreviate brand names, or otherwise promote specific prescription products to the public, because the law explicitly prohibits us from doing so. This is not a stylistic choice; it is a regulatory requirement, and clinics that work around it tend to be the same clinics that work around other clinical and ethical limits.
When this might be funded through Medicare
In specific clinical circumstances, axillary hyperhidrosis treatment is claimable through the Medicare Benefits Schedule if defined criteria are met (severe disease unresponsive to topical therapy, with adequate documentation) and if the relevant referral pathway is followed. The threshold and the documentation requirements have been progressively tightened, and the practical accessibility varies. We discuss the current eligibility framework at consultation rather than promising a particular outcome.
Working with Corey
Corey Anderson is the only practitioner at Core Aesthetics. Registered with the Nursing and Midwifery Board of Australia since January 1996 (AHPRA NMW0001047575), Corey runs a one practitioner, low volume model from Oakleigh. For hyperhidrosis treatment, the consistency of injection technique and treatment mapping across years of repeated visits supports the kind of incremental refinement that produces stable, predictable results.
Patients see Corey at every visit. The treatment record carries dose, mapping pattern and response duration forward across years.
Getting started
If the description on this page sounds familiar (excessive underarm sweating, present for years, not responding adequately to topical strategies, interfering with daily life), a consultation is the next step. The consultation is a clinical assessment, not a treatment commitment. If history suggests the presentation requires evaluation outside our scope, we say so and refer back to general practice. If the indication is clear and the patient is ready to proceed, treatment can be performed in the same visit. Results vary between individuals.
Core Aesthetics is at 12A Atherton Road, Oakleigh, in Melbourne south east. Booking is direct online or by contacting the clinic.
A note on terminology and accuracy
Patients sometimes describe themselves as having heavy sweating without recognising that the pattern they describe matches the diagnostic criteria for primary focal hyperhidrosis. The reverse also occurs: patients use the word hyperhidrosis to describe normal physiological sweating in a hot environment or under exertion. The clinical definition is specific. It refers to sweating that exceeds thermoregulatory requirement and that occurs in defined patterns. Naming the condition accurately matters because it changes the conversation from one about personal coping strategies to one about a recognised medical condition with established treatment options.
This precision is also part of why we discourage informal self diagnosis from online sources without clinical assessment. Conditions that look identical at the level of patient experience can have different underlying causes that warrant different management. The starting point is a clinical history with a practitioner who has seen the full range of presentations.
Why the consultation lens is medical, not cosmetic
Hyperhidrosis treatment uses the same regulatory class of product that is used in many cosmetic indications. The patient sometimes arrives expecting a cosmetic style consultation. The conversation is not that. We are addressing a condition with measurable functional impact, using a treatment with strong published evidence, in a clinical decision making framework that more closely resembles the management of any other recognised medical condition. The aesthetic treatments labelling is incidental to the actual clinical content.
A note on broader context
Hyperhidrosis sits at the intersection of dermatology, neurology and primary care. The condition is recognised in international clinical guidelines, including those from the International Hyperhidrosis Society and various national dermatology associations, with broadly consistent recommendations for assessment and treatment. The Australian context is shaped by the existing Medicare framework, the prescribing scope of registered nurses and nurse practitioners, and the specific provisions of the Therapeutic Goods Advertising Code that apply to the prescription products used in treatment.
For a patient navigating this for the first time, the practical implication is that the condition is well characterised, the treatment options are well evidenced, and the path from initial conversation to treatment can be straightforward when the indication is clear. The slow path from first symptoms to first consultation is more often about awareness than about access.
A short historical note
Botulinum toxin was first studied in clinical settings in the 1970s for strabismus and other conditions involving inappropriate muscle activity. Its application to hyperhidrosis was reported in the late 1990s and was recognised as a reproducible clinical observation: that the same product which dampened muscular contraction also dampened sweating in adjacent skin. The mechanism (interruption of acetylcholine release at the neuro glandular junction in eccrine sweat glands) was characterised over the subsequent decade, and the treatment is now established within international clinical guidelines for axillary hyperhidrosis where topical therapy has been inadequate.
A note on living with the condition
Patients who live with hyperhidrosis often describe a kind of accumulated fatigue from managing it. The constant low grade vigilance about sweat patches, fabric choice, social situations and the small adjustments that build up across a day is exhausting in a way that is difficult to convey to people who have not lived it. The clinical literature recognises this and uses validated quality of life instruments to capture it. Treatment, when it is appropriate and well delivered, often relieves the cognitive load as much as it relieves the physical sweat.
Compensatory sweating: what is and is not known
The concern about compensatory sweating is legitimate and worth addressing directly. After surgical sympathectomy, compensatory sweating in untreated body regions is common, sometimes severe, and permanent. After focal neuromodulator treatment of the underarms, compensatory sweating is rare and, when reported, typically mild and transient. The reversibility of neuromodulator treatment is one of the central reasons it has displaced surgical sympathectomy as the preferred approach for most focal axillary cases.
How Patients Find Their Way To Diagnosis And What Comes Next
Many patients with primary hyperhidrosis live with the condition for years before formally seeking treatment. The presentation is often gradual, the impact accumulates slowly, and the social and professional adaptation that develops around it can mask the extent of the underlying problem until a specific event prompts re evaluation. The diagnostic conversation at a hyperhidrosis consultation is typically the first time the patient has been asked structured questions about onset, distribution, severity, family history, and the practical patterns of daily impact. The conversation itself often produces useful clarification for the patient about what has been happening.
The clinical assessment establishes whether the presentation fits the primary pattern (idiopathic, focal, bilateral, symmetric, onset in childhood or adolescence, absent during sleep, with positive family history in many cases) or whether features warrant medical evaluation for a secondary cause. Patients whose history fits the primary pattern proceed to treatment options discussion. Patients with features suggesting a secondary cause are referred for medical evaluation before injectable treatment is considered. The recommendation is grounded in clinical caution rather than in any reluctance to treat; the underlying cause investigation often reassures rather than reveals anything serious, and the injectable conversation can resume after that step is complete.
Further Reading on Excessive Sweating
For an overview of the clinical options available for managing excessive sweating, see our article: Best Solutions for Excessive Sweating.
Is this for you?
Consider booking a consultation if
- You are researching hyperhidrosis as a recognised medical condition and want a clear, clinical explanation
- You suspect you may have primary focal axillary hyperhidrosis and want assessment to confirm the indication
- You have tried topical aluminium chloride antiperspirants and found them inadequate or irritating
- You are 18 or older and otherwise in general good health
This may not be for you if
- You are pregnant, trying to conceive, or breastfeeding
- You have a neuromuscular condition that contraindicates neuromodulator treatment, or a known allergy to the active ingredient
- Your sweating is generalised, sudden in onset in adulthood, occurs during sleep or is associated with other systemic symptoms (these warrant evaluation outside our scope)
- You are under 18
Suitability is confirmed at consultation. This list is general guidance, not a substitute for clinical assessment.
Frequently asked questions
What is the difference between primary and secondary hyperhidrosis?
Primary hyperhidrosis is idiopathic, focal (affecting specific regions like underarms, palms, soles, face), bilateral and symmetrical, often beginning in adolescence and occurring during waking hours. Secondary hyperhidrosis is caused by an underlying medical condition or medication, is often generalised rather than focal, can begin in adulthood, may occur during sleep, and is treated by addressing the underlying cause rather than by neuromodulator injection of the affected region.
How is primary focal hyperhidrosis diagnosed?
Diagnosis is clinical, based on history and presentation. The validated criteria require focal visible excessive sweating of at least six months duration without apparent cause, with at least two of: bilateral and symmetrical pattern, impairment of daily activities, frequency of at least once weekly, age of onset under 25, positive family history, or cessation during sleep. A starch iodine test or gravimetric measurement can support diagnosis or treatment planning but is not required.
What body regions are commonly affected?
Primary focal hyperhidrosis most often affects the underarms (axillary), palms (palmar), soles (plantar), or face and scalp (craniofacial). Many patients have more than one affected region. The commonest treated region in cosmetic practice is the underarm. Palmar treatment is technically more demanding and carries a small transient grip weakness risk. Plantar treatment is possible but often less satisfactory.
What treatment options are available?
First line is topical aluminium chloride antiperspirant in over the counter or prescription strength. Where topical treatment is inadequate, second line for axillary disease is neuromodulator injection. Other modalities include microwave thermolysis (a different category of treatment), iontophoresis (mainly for palmar disease), oral anticholinergic medications (with side effect considerations), and rarely surgical sympathectomy (now usually reserved for failure of other approaches due to compensatory sweating risk).
How does neuromodulator treatment work for hyperhidrosis?
It blocks acetylcholine release at the neuro glandular junction between sympathetic sudomotor nerves and eccrine sweat glands. Without that signal, sweat production from the treated glands is substantially reduced for the duration of the blockade. Effect is reversible. Median first treatment duration is around five and a half months and median repeat treatment duration around eight and a half months in published clinical studies, with substantial individual variation.
Will I sweat more elsewhere if my underarms are treated?
Compensatory sweating after focal axillary neuromodulator treatment is rare and, when reported, typically mild. This is in contrast to surgical sympathectomy, which is associated with a substantial risk of permanent compensatory sweating elsewhere. The reversibility of neuromodulator treatment is one of the main reasons it has displaced surgery for most focal axillary cases.
How often does treatment need to be repeated?
Typically two to three times per year depending on individual duration of effect. First treatments often last between four and seven months. Repeat treatments tend to last slightly longer as cumulative effect builds. The plan is built around clinical assessment at follow up rather than a fixed retreatment calendar.
Is hyperhidrosis treatment claimable through Medicare?
In specific clinical circumstances and with appropriate referral, axillary hyperhidrosis treatment is claimable through the Medicare Benefits Schedule for severe disease unresponsive to topical therapy, with adequate documentation. The threshold and documentation requirements have been progressively tightened. We discuss the current eligibility framework at consultation rather than promising a particular outcome.
Should I try other treatments before considering injectable hyperhidrosis treatment?
Clinical guidelines generally recommend trialling prescription-strength antiperspirant before considering injectable treatment for axillary hyperhidrosis. If topical approaches have been insufficient or poorly tolerated, injectable prescription neuromodulator is a well-established option. Your medical history and previous treatment attempts will be reviewed at consultation.
Is it safe to have hyperhidrosis treatment in both underarms at the same appointment?
Treating both axillae at a single appointment is standard clinical practice for hyperhidrosis and is generally well tolerated. The total dose used across both sides is within established therapeutic ranges. As with all prescription injectable treatment, individual health factors are reviewed at consultation before proceeding.
Why does hyperhidrosis treatment eventually wear off and need repeating?
Prescription neuromodulator works by temporarily disrupting the nerve signals that stimulate sweat glands. As the product metabolises over time, nerve function gradually returns and sweating resumes. Most patients find treatment lasts between four and twelve months, with individual variation influenced by metabolism, activity level and dose used.